# Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

> **NCT02415036** · PHASE2 · TERMINATED · sponsor: **Delcath Systems Inc.** · enrollment: 17 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma

## Interventions

- **DEVICE:** Delcath Hepatic Delivery System
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT02415036
- **Lead sponsor:** Delcath Systems Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2018-10
- **Final completion:** 2018-12
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Limited enrollment
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415036, "Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02415036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*